Cheng Sohanya Roshan

SEC source: 0001193125-26-226652 · ownership.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,940

F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-26-226652 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,264

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026.

SEC source: 0001865796-26-000003 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,317

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-26-035687 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,921

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

SEC source: 0001193125-25-241468 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,506

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.

SEC source: 0001193125-25-205042 · ownership.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,856

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-25-205042 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,181

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

F2 · balance_after: Includes 922 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025.

SEC source: 0000950170-25-034743 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,314

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-032323 · ownership.xml · derivative · entry 4

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,166

Underlying: Common Stock · 9,166 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F5 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032323 · ownership.xml · derivative · entry 3

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,833

Underlying: Common Stock · 10,833 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F5 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032323 · ownership.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,759

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · shares: Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032323 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,176

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · balance_after: Includes 824 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2022 Employee Stock Purchase Plan on October 31, 2024.

SEC source: 0001104659-24-113518 · tm2427268-2_4seq1.xml · derivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Common Stock · 38,700 shares

Expires 2034-10-31

F1 · derivative.exercise_date: The shares underlying this option vest over three years in equal monthly installments following October 31, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.

SEC source: 0000950170-24-103998 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,051

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · balance_after: Includes 15,898 shares acquired under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2024.

SEC source: 0000950170-24-025189 · ownership.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,509

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025189 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,618

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-023285 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420,458

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.

SEC source: 0000950170-24-007621 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,499

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date.

F2 · balance_after: Includes 3,246 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. Amended and Restated 2013 Employee Stock Purchase Plan.

SEC source: 0001209191-23-048159 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,086

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-036248 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 211,501

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · balance_after: Includes 2,653 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 28, 2023.

SEC source: 0001209191-23-014861 · doc4.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,687

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-014861 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,926

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

F2 · balance_after: Includes 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2022.

SEC source: 0001209191-22-048395 · doc4.xml · derivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-08-30

F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048395 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,949

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-036812 · doc4.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,949

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-036812 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,434

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-014622 · doc4.xml · derivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 108,000 shares

Expires 2032-02-27

F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014622 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,500

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-21-044423 · doc4.xml · derivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · SVP Sales & Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2031-06-29

F2 · derivative.exercise_date: This option was granted on June 30, 2021. The shares underlying this option vest as to 25% of the shares on June 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-044423 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · SVP Sales & Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on June 7, 2022, the first anniversary of Ms. Cheng's date of hire, with the remaining 50% vesting on June 7, 2023.